13F

Stock

Cadrenal Therapeutics, Inc.

CVKD · held by 20 managers

Reported value

$823.9K

Holders

20

+0 new · −0 exited

Holders’ est. mark

−$6.42K

Price effect on 3 books still in the name

Largest holder

$365.5K

Vanguard

Notable conviction

Share of each notable manager’s 13F book.

Holder count by quarter

Who holds it

Notable only
InvestorSharesValueEst. markChange
Vanguard53.9K$365.5KHeld
DRW Securities, LLC25.2K$170.5KHeld
GEODE CAPITAL MANAGEMENT, LLC14.5K$98.5KHeld
LPL Financial LLC13K$88.1KHeld
JPMORGAN CHASE & CO7.5K$50.9KHeld
BlackRock, Inc.3.52K$23.9KHeld
MORGAN STANLEY1.08K$7.32K−$6.2KCut−$4.85K
UBS Group AG1.04K$7.08KHeld
Tower Research Capital LLC (TRC)532$3.61KHeld
OSAIC HOLDINGS, INC.500$3.39KHeld
Rockefeller Capital Management L.P.300$2.03KHeld
Clearstead Advisors, LLC150$1.02KHeld
HARBOUR INVESTMENTS, INC.100$678Held
WELLS FARGO & COMPANY/MN99$671Held
Archer Investment Corp35$237Held
IFP Advisors, Inc30$203−$212Cut−$212
Farther Finance Advisors, LLC25$170Held
CALDWELL SUTTER CAPITAL, INC.5$34Held
BANK OF AMERICA CORP /DE/1$7−$7Cut−$7
CURIO WEALTH, LLC1$7Held

Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.